Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries

Objectives: Large-scale observational cohorts may be used to study the effectiveness and rare side effects of biological disease-modifying anti-rheumatic drugs (bDMARDs) in ankylosing spondylitis (AS), but may be hampered by differences in baseline characteristics and disease activity across countri...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2018-11, Vol.47 (6), p.465-474
Main Authors: Glintborg, B, Lindström, U, Aaltonen, K, Kristianslund, EK, Gudbjornsson, B, Chatzidionysiou, K, Askling, J, Nordström, D, Hetland, ML, Di Giuseppe, D, Dreyer, L, Kristensen, LE, Jørgensen, TS, Eklund, K, Grondal, G, Ernestam, S, Joensuu, J, Törmänen, MRK, Skydsgaard, H, Hagfors, J, Kvien, TK, Lie, E, Fagerli, K, Geirsson, AJ, Jonsson, H, Provan, SA, Krogh, NS, Jacobsson, LTH
Format: Article
Language:English
Subjects:
agents
danbio
dmards
drug survival
exposure
infliximab
Medicin och hälsovetenskap
psoriatic-arthritis
registers
Reumatologi och inflammation
rheumatoid-arthritis
Rheumatology and Autoimmunity
tnf-inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: Large-scale observational cohorts may be used to study the effectiveness and rare side effects of biological disease-modifying anti-rheumatic drugs (bDMARDs) in ankylosing spondylitis (AS), but may be hampered by differences in baseline characteristics and disease activity across countries. We aimed to explore the research infrastructure in the five Nordic countries regarding bDMARD treatment in AS. Method: This observational cohort study was based on data from biological registries in Denmark (DANBIO), Sweden (SRQ/ARTIS), Finland (ROB-FIN), Norway (NOR-DMARD), and Iceland (ICEBIO). Data were collected for the years 2010-2016. Registry coverage, registry inventory (patient characteristics, disease activity measures), and national guidelines for bDMARD prescription in AS were described per country. Incident (first line) and prevalent bDMARD use per capita, country, and year were calculated. In AS patients who started first line bDMARDs during 2010-2016 (n = 4392), baseline characteristics and disease activity measures were retrieved. Results: Registry coverage of bDMARD-treated patients ranged from 60% to 95%. All registries included extensive prospectively collected data at patient level. Guidelines regarding choice of first line drug and prescription patterns varied across countries. During the period 2010-2016 prevalent bDMARD use increased (p 
ISSN:0300-9742
1502-7732
1502-7732
DOI:10.1080/03009742.2018.1444199